Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Liabilities: 2020-2024

Historic Total Liabilities for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $191.3 million.

  • Arcutis Biotherapeutics' Total Liabilities fell 24.16% to $212.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.9 million, marking a year-over-year decrease of 24.16%. This contributed to the annual value of $191.3 million for FY2024, which is 24.28% down from last year.
  • Arcutis Biotherapeutics' Total Liabilities amounted to $191.3 million in FY2024, which was down 24.28% from $252.7 million recorded in FY2023.
  • Arcutis Biotherapeutics' Total Liabilities' 5-year high stood at $252.7 million during FY2023, with a 5-year trough of $27.6 million in FY2020.
  • Over the past 3 years, Arcutis Biotherapeutics' median Total Liabilities value was $239.7 million (recorded in 2022), while the average stood at $227.9 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Total Liabilities soared by 299.58% in 2021 and then decreased by 24.28% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Liabilities (Yearly) stood at $27.6 million in 2020, then soared by 299.58% to $110.5 million in 2021, then soared by 116.97% to $239.7 million in 2022, then climbed by 5.43% to $252.7 million in 2023, then dropped by 24.28% to $191.3 million in 2024.